

134 illustrated slides on the Global Biosimilar Market with a specific focus on the French market to better Know - Understand & Decide

Current and potential market

A growing share of all drugs are biologic, with biosimilars and other non-original biologic products now taking a growing share of the total market

The biologic market



Biosimilar market players

Incumbents in the biosimilar market are predominantly emerging-market players from India, China and South Korea

Current players in the biosimilar market

M	R&D	Marketed products													
		ESA	G-CSF	Hep. B vaccine	Interferon	HGH	Insulin	SK, tPA	mAb	FSH	Others ¹	Partnerships			
+		M/R&D	M/R&D												
+		M/R&D	M/R&D												
+		M/R&D	M/R&D												
+		M	M/R&D												
+		M	M/R&D												


Note: biosimilars are those biologic dedicated regulatory pathway as innovative brands that have not a
Sources: The Global Use of Medicines Company (financial reports – Sanofi)
Global Biosimilar Drugs M

10. French biosimilar market highlight

10.4. Biosimilar market forecasts by 2017

ESA biosimilars should benefit from Aranesp's patent loss in mid 2016; sales in value could reach between € 20 M and € 44 M in the end of 2017, depending on the scenario

Forecasts – ESA



Sources: GERS Data (December 2014) – Smart Pharma Consulting Analyses
 Global Biosimilar Drugs Market Outlooks
 Smart Pharma Consulting
 February 2015

New Report from Smart Pharma Consulting

Global Biosimilar Drugs Market Outlooks

Specific focus on the French market (2017 forecasts)

February 2015

Smart Pharma Consulting

1, rue Houdart de Lamotte – 75015 Paris – France
 Tel.: +33 6 11 96 33 78 – Fax: +33 1 45 57 46 59
 E-mail: jpmpey@smart-pharma.com
 Website: www.smart-pharma.com

Summary

1. Introduction
2. Definitions
3. Bio-betters
4. Drug development process
5. Registration guidelines
6. Market access process
7. Current and potential market
8. Biosimilar market players
9. Biosimilar drugs drivers and limiters
10. French biosimilar market highlight (incl. sales forecasts¹)
11. Conclusion
12. Appendices

¹ HGH, ESA, G-CSF, Follitropin α, Etanercept, Insulin glargine, Infliximab, Trastuzumab, Rituximab

To order this new report
 Use the order form printed inside or contact Smart Pharma Consulting directly

Smart Pharma Consulting

1, rue Houdart de Lamotte – 75015 Paris – France
 Tel.: +33 6 11 96 33 78 – Fax: +33 1 45 57 46 59
 E-mail: jpmpey@smart-pharma.com
 Website: www.smart-pharma.com

Order Form

Global Biosimilar Drugs Market Outlooks

- 1** I would like to order an electronic version (PowerPoint): of the report “Global Biosimilar Drugs Market Outlooks” (134 pages) published in February 2015 in English

at the price of: € 2,500 € (excl. taxes)
- 2** I would like to order an electronic version (PowerPoint) of the report ”Le Marché des génériques en France – 2014” (137 pages) published in October 2014 in French (see details on our website: www.smart-pharma.com)

at the price of: € 2,500 € (excl. taxes)
- 3** I would like to order an electronic version (PowerPoint) of these two reports:

at the special price of: € 4,500 € (excl. taxes)

I would like to pay:

- By check in € to Smart Pharma Consulting
- By bank transfer in € to: Credit du Nord – IBAN: FR76 3007 6021 1716 5131 0020 092

Please fill out and address your order form to:

Email : jmpeny@smart-pharma.com Fax : +33 1 45 57 46 59 Address: Smart Pharma Consulting - 1, rue Houdart de Lamotte - 75015 Paris – France

The report will be sent by e-mail with an invoice

Billing address

Last Name: _____

First Name: _____

Position: _____

Company: _____

Address: _____

ZIP code: _____

Country: _____

E-mail: _____

Phone number: _____